FDA Fast-Tracks Zymeworks’ New Ovarian Cancer Drug ZW191

Zymeworks receives U.S. FDA Fast Track Designation for ZW191, its FRα-targeting antibody-drug conjugate for advanced platinum-resistant ovarian cancer.